摘要
非霍奇金淋巴瘤(NHL)代表一组异质性淋巴衍生恶性肿瘤,从惰性到高度侵袭性不等。根据肿瘤细胞的来源,本病可分为B细胞淋巴瘤、T/NK细胞淋巴瘤。在B-NHL复发/难治性患者中,挽救性化疗和自体干细胞移植能够治愈50%的患者,而另一半患者的结果令人沮丧,中位总生存期不到12个月。随着非霍奇金淋巴瘤(NHL)治疗的进步,为了提高B-NHL患者的生存率,靶向药物疗法,正在彻底改变B细胞非霍奇金淋巴瘤(B-NHL)的治疗格局。本文就近年来B-NHLs靶向药物的治疗研究作一简要综述。
Non Hodgkin’s lymphoma (NHL) represents a group of heterogeneous lymphoid derived malignant tumors, ranging from inert to highly invasive. According to the source of tumor cells, this disease can be divided into B-cell lymphoma and T/NK cell lymphoma. In B-NHL recurrent/refractory patients, salvage chemotherapy and autologous stem cell transplantation can cure 50% of patients, while the results of the other half of patients are disappointing, with a median overall survival of less than 12 months. With the advancement of non Hodgkin’s lymphoma (NHL) treatment, in order to improve the survival rate of B-NHL patients. Targeted drug therapy is completely changing the treatment pattern of B-cell non Hodgkin’s lymphoma (B-NHL). This article provides a brief review of recent research on targeted drug therapy for B-NHLs.
出处
《临床个性化医学》
2024年第2期472-479,共8页
Journal of Clinical Personalized Medicine
